Details of the Drug Combination

General Information of Drug Combination (ID: DCD9ZG7)

Drug Combination Name
Labetalol Nifedipine
Indication
Disease Entry Status REF
Elevated Blood Pressure Phase 2 [1]
Component Drugs Labetalol   DMK8U72 Nifedipine   DMSVOZT
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Labetalol
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Hypertension, pregnancy-induced N.A. Approved [3]
Malignant essential hypertension BA00 Approved [3]
Labetalol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor Alpha-1 (ADRA1) TTG28O6 NOUNIPROTAC Antagonist [6]
------------------------------------------------------------------------------------
Labetalol Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Labetalol Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [11]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [9]
UDP-glucuronosyltransferase 2B4 (UGT2B4) DENUPDX UD2B4_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Labetalol Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases ADR [12]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [13]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [14]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Activity [13]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Increases Expression [15]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Decreases Activity [16]
Beta-1 adrenergic receptor (ADRB1) OTQBWN4U ADRB1_HUMAN Decreases Activity [16]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Decreases Activity [17]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Increases Activity [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)
Indication(s) of Nifedipine
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [4]
Premature labour JB00 Approved [5]
Nifedipine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Voltage-gated L-type calcium channel (L-CaC) TTXHYV6 NOUNIPROTAC Modulator [19]
------------------------------------------------------------------------------------
Nifedipine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [20]
------------------------------------------------------------------------------------
Nifedipine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [21]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [22]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [23]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [24]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Metabolism [25]
------------------------------------------------------------------------------------
Nifedipine Interacts with 39 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [22]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [26]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [27]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [28]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [29]
Cytochrome P450 2J2 (CYP2J2) OTJBTEH8 CP2J2_HUMAN Decreases Activity [30]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [31]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Activity [32]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [33]
Insulin-like growth factor II (IGF2) OTJ4O6MW IGF2_HUMAN Decreases Response To Substance [34]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [35]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Affects Expression [36]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Increases Expression [37]
Apolipoprotein A-II (APOA2) OTQ3HGTC APOA2_HUMAN Increases Expression [37]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Activity [38]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [39]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Activity [40]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [41]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Response To Substance [34]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Affects Response To Substance [42]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [43]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [44]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Increases Expression [45]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Decreases Expression [46]
Fibroblast growth factor 7 (FGF7) OTGK6ANL FGF7_HUMAN Increases Expression [47]
Potassium voltage-gated channel subfamily A member 3 (KCNA3) OTXSP3AA KCNA3_HUMAN Decreases Activity [48]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [49]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Decreases Expression [49]
Myosin-11 (MYH11) OTVNVWY3 MYH11_HUMAN Increases Expression [49]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Increases Expression [46]
Oxidized low-density lipoprotein receptor 1 (OLR1) OTS44RIC OLR1_HUMAN Decreases Expression [50]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [51]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Localization [43]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [41]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Decreases Expression [46]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [38]
Myosin-7 (MYH7) OT4Z9T8N MYH7_HUMAN Decreases Response To Substance [52]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases ADR [12]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Increases ADR [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 39 DOT(s)

References

1 ClinicalTrials.gov (NCT05955040) Treatment of Elevated Blood Pressures in Early Pregnancy
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7207).
3 Labetalol FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2514).
5 Nifedipine FDA Label
6 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
9 Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
10 Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
11 Drug Interactions Flockhart Table
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13 Hemodynamic and humoral effects of intravenous dilevalol in patients with moderate hypertension. Am J Cardiol. 1989 Jun 5;63(19):34I-37I. doi: 10.1016/0002-9149(89)90126-4.
14 Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension. Aust N Z J Med. 1976 Aug;6(3 Suppl):83-8. doi: 10.1111/j.1445-5994.1976.tb03341.x.
15 Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf). 1982 Jun;16(6):615-9. doi: 10.1111/j.1365-2265.1982.tb03178.x.
16 Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism. Am J Cardiol. 1989 Jun 5;63(19):3I-6I. doi: 10.1016/0002-9149(89)90120-3.
17 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
18 Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011 Sep;16(8):878-85. doi: 10.1177/1087057111413919. Epub 2011 Aug 22.
19 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
22 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
23 Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
24 In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
25 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
26 Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
27 Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.
28 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
29 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
30 Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
31 Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
32 Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987 Dec;5(4):S139-42. doi: 10.1097/00004872-198712004-00023.
33 Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol. 2000 Jan;71(1):44-9. doi: 10.1902/jop.2000.71.1.44.
34 Insulin-like growth factors (IGF) I and II utilize different calcium signaling pathways in a primary human parathyroid cell culture model. World J Surg. 2006 Mar;30(3):333-45. doi: 10.1007/s00268-005-0339-8.
35 Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol. 2017 Jul;37(7):863-872. doi: 10.1002/jat.3435. Epub 2017 Jan 31.
36 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
37 Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology. 1991 Sep;42(9):681-90. doi: 10.1177/000331979104200901.
38 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
39 Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation. J Hypertens. 2008 Apr;26(4):737-46. doi: 10.1097/HJH.0b013e3282f4d1bd.
40 High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
41 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
42 The effect of basic fibroblast growth factor on cell cycle in human gingival fibroblasts from nifedipine responder and non-responder. J Oral Sci. 2004 Mar;46(1):37-44. doi: 10.2334/josnusd.46.37.
43 Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
44 Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Am J Hypertens. 1999 Jan;12(1 Pt 1):73-5. doi: 10.1016/s0895-7061(98)00217-9.
45 Effect of nifedipine on endothelial function in normotensive smokers: potential contribution of increase in circulating hepatocyte growth factor. J Hum Hypertens. 2004 Oct;18(10):701-5. doi: 10.1038/sj.jhh.1001727.
46 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
47 Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine. 2000 Oct;12(10):1566-9. doi: 10.1006/cyto.2000.0756.
48 A cell-based Rb(+)-flux assay of the Kv1.3 potassium channel. Assay Drug Dev Technol. 2007 Jun;5(3):373-80. doi: 10.1089/adt.2006.004.
49 Nifedipine inhibits vascular smooth muscle cell dedifferentiation via downregulation of Akt signaling. Hypertension. 2010 Aug;56(2):247-52. doi: 10.1161/HYPERTENSIONAHA.110.149781. Epub 2010 Jun 7.
50 Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J Cardiovasc Pharmacol. 2002 Jul;40(1):146-52. doi: 10.1097/00005344-200207000-00018.
51 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
52 CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur Heart J. 2018 Nov 14;39(43):3879-3892. doi: 10.1093/eurheartj/ehy249.